Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
- March -
April
-
May
-
June
-
July
-
August
-
September
-
Oktober
-
November
-
December
|
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
- 2020 -
2021
-
2022
-
2023
-
2024
-
2025
March 2020 - 32 products
IP
CI
Metrissa 2 mg
28
39.48
59.45
10 %
Coated tablets: Dienogestum 2 mg
Gynial AG
B / SL / SG
FB
G
IP
CI
Metrissa 2 mg
3 x 28
100.67
126.20
10 %
Coated tablets: Dienogestum 2 mg
Gynial AG
B / SL / SG
FB
G
IP
CI
Brimo-Vision 2 mg/ml
60 x 0.35 ml
8.52
25.70
10 %
Augentropfen (Einzeldosen): Brimonidini Tartras 2 mg/ml
OmniVision AG
B / SL / SG
FB
G
IP
CI
Brimo-Vision 2 mg/ml
180 x 0.35 ml
19.94
38.10
10 %
Augentropfen (Einzeldosen): Brimonidini Tartras 2 mg/ml
OmniVision AG
B / SL / SG
FB
G
L
IP
Bortezomib Accord 1 mg
126.04
153.50
10 %
Pulver zur Herstellung einer lnjektionslösung: Bortezomibum 1 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
Bortezomib Accord 3.5 mg
372.78
421.85
10 %
Pulver zur Herstellung einer lnjektionslösung: Bortezomibum 3.5 mg
Accord Healthcare AG
A / SL / SG
FB
G
L
IP
CI
Idacio 40 mg/ 0.8 ml
2
742.19
823.50
10 %
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.8ml
Fresenius Kabi
(Schweiz) AG
B / SL
FB
G
L
IP
Sarclisa 100 mg/5 mL
504.35
564.95
10 %
Concentrate for infusion: Isatuximabum 100mg / 5ml
Sanofi-Aventis
(Suisse) SA
A / SL
FB
G
L
IP
Sarclisa 500 mg/25 mL
2521.75
2758.95
10 %
Concentrate for infusion: Isatuximabum 500mg / 25ml
Sanofi-Aventis
(Suisse) SA
A / SL
FB
G
L
IP
CI
Piqray 150 mg
28
1483.58
1629.90
10 %
Coated tablets: Alpelisibum 150 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Piqray 150 mg
56
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 150 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg
28
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 200 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg + 50 mg
14
1483.58
1629.90
10 %
Coated tablets: Alpelisibum 200 mg
Coated tablets: Alpelisibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
Piqray 200 mg + 50 mg
28
2982.21
3259.75
10 %
Coated tablets: Alpelisibum 200 mg
Coated tablets: Alpelisibum 50 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Zykadia
84
4003.77
4370.75
10 %
Coated tablets: Ceritinibum 150 mg
Novartis Pharma
Schweiz AG
A / SL
FB
G
L
IP
CI
Rybelsus 3 mg
30
101.42
126.70
10 %
Tablets: Semaglutidum 3 mg
Novo Nordisk Pharma AG
B / SL
FB
G
L
IP
Rybelsus 7 mg
30
101.42
126.70
10 %
Tablets: Semaglutidum 7 mg
Novo Nordisk Pharma AG
B / SL
FB
G
L
IP
Rybelsus 7 mg
90
304.25
347.30
10 %
Tablets: Semaglutidum 7 mg
Novo Nordisk Pharma AG
B / SL
FB
G
L
IP
Rybelsus 14 mg
30
101.42
126.70
10 %
Tablets: Semaglutidum 14 mg
Novo Nordisk Pharma AG
B / SL
FB
G
L
IP
Rybelsus 14 mg
90
304.25
347.30
10 %
Tablets: Semaglutidum 14 mg
Novo Nordisk Pharma AG
B / SL
FB
G
L
IP
CI
Vyndaqel 61 mg
30
9422.28
9975.05
10 %
Soft capsules: Tafamidisum 61 mg
Pfizer AG
B / SL
FB
G
L
IP
CI
Viferol D3 25'000 UI/ml
4
5.59
15.30
10 %
Solution (oral): Cholecalciferolum 25000 UI/ml
OM Pharma Suisse SA
B / SL
FB
G
L
IP
CI
Idacio 40 mg/0.8 ml
2
742.19
823.50
10 %
Injektionslösung im Fertigpen: Adalimumabum 40mg / 0.8ml
Fresenius Kabi
(Schweiz) AG
B / SL
FB
G
IP
CI
Idacio 40 mg/ 0.8 ml
6
PR
PR
k.A.
Injection solution in prefilled syringe: Adalimumabum 40mg / 0.8ml
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
Sarclisa 100 mg/5 mL
3
PR
PR
k.A.
Concentrate for infusion: Isatuximabum 100mg / 5ml
Sanofi-Aventis
(Suisse) SA
A
FB
G
IP
CI
Metrissa 2 mg
6 x 28
PR
PR
k.A.
Coated tablets: Dienogestum 2 mg
Gynial AG
B
FB
G
IP
CI
Nerlynx 40 mg
180
PR
PR
k.A.
Coated tablets: Neratinibum 40 mg
Pierre Fabre Pharma SA
A
FB
G
IP
Piqray 200 mg
14
PR
PR
k.A.
Coated tablets: Alpelisibum 200 mg
Novartis Pharma
Schweiz AG
A
FB
G
IP
CI
Vyndaqel 20 mg
30
PR
PR
k.A.
Soft capsules: Tafamidisum Megluminum 20 mg
Pfizer AG
B
FB
G
IP
CI
Verkazia
120 x 0.3 ml
PR
PR
k.A.
Augentropfen Emulsion: Ciclosporinum 1 mg/ml
Santen SA
B
FB
G
IP
CI
Idacio 40 mg/0.8 ml
6
PR
PR
k.A.
Injektionslösung im Fertigpen: Adalimumabum 40mg / 0.8ml
Fresenius Kabi
(Schweiz) AG
B
FB
G
IP
CI
neotylol Grippe
12
PR
PR
k.A.
Pulver zur Herstellung einer Lösung zum Einnehmen: 4 Active Agents
NOBEL Pharma Schweiz AG
D
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home
